Your session is about to expire
← Back to Search
Copanlisib for Acute Lymphoblastic Leukemia
Study Summary
This trial will study how well a drug called copanlisib works in patients with relapsed or refractory B-ALL.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 24 Patients • NCT02631590Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are an adult (18 years or older) with B-cell acute lymphoblastic leukemia that has come back or is not responding to treatment. This includes leukemia in the bone marrow, other parts of the body, or the central nervous system. You may or may not have had a previous stem cell transplant.Your high blood pressure is not well controlled even with the best medicine available, according to the doctor's evaluation.You have or had a lung disease called interstitial lung disease or autoimmune pneumonitis.You have a history of type 1 diabetes.You have ongoing infections that are getting worse or not responding to treatment.
- Group 1: Copanilisib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment pioneering a new approach to treatment?
"Since 2012, Bayer has sponsored research into copanlisib. After the first study in that year with 227 participants, it was given Phase 2 drug approval. Nowadays, there are 32 active trials of this medication across 983 cities and 46 countries."
Are there any prior experimental findings concerning Copanlisib?
"Currently, there are 32 studies that focus on Copanlisib with two of them in their terminal stage. Most trials for the drug take place in Houston, Texas yet an additional 2118 sites worldwide host experiments regarding its efficacy."
Is this experiment presently open to participating subjects?
"Affirmative. According to the information on clinicaltrials.gov, recruitment for this research project is still in progress after being initially posted on June 21st 2021 and last updated on June 28th 2022. The study requires 10 volunteers from a single site."
What population is participating in the experiment?
"Affirmative. According to the information on clinicaltrials.gov, this research endeavour is currently recruiting participants after being first posted on June 21st 2021 and last updated on June 28th 2022. This trial requires a total of 10 patients from 1 medical centre for enrolment."
Share this study with friends
Copy Link
Messenger